BiondVax Pharmaceuticals Ltd. is developing an innovative universal
flu (influenza) vaccine, providing a multi-season/multi-strain and longterm
protection against a variety of flu viruses. The current formulation
of the vaccine is slated for clinical trials in humans in 2009.
BiondVax’s universal vaccine is based on research carried out for
the past 20 years by Weizmann Institute Professor Ruth Arnon who
serves as the company’s Scientific Advisor. Prof. Arnon is well-known
for her part in ground-breaking research on multiple sclerosis that led
to Teva’s Copaxone drug, which this July passed the billion dollar
mark in sales.
BiondVax’s innovative vaccine represents a quantum leap in the flu
vaccine arena, as it is based on a combination of conserved viral
elements, common to virtually all existing and future flu virus strains,
thus providing the broadest possible protection. BiondVax’s vaccine
will potentially demonstrate greater efficacy levels, longer vaccination
periods and a much wider scope of virus strain coverage than any
other vaccine in the market to date.
The potential efficacy of BiondVax’s vaccine in dealing with Avian flu,
a global threat that could claim 40 million lives according to the WHO,
makes the company a significant player in the struggle against this
According to analysts, global sales of flu vaccines are expected to
reach $4 billion by 2012.
BiondVax Pharmaceuticals, a publicly traded company located
in the Weizmann Science Park in Ness Ziona, is dedicated to
developing novel vaccines against a variety of infectious diseases and
Watch movie >>